Interestingly, bevacizumab abolished VEGF-induced tube formation, but not EPO-induced tube formation

Interestingly, bevacizumab abolished VEGF-induced tube formation, but not EPO-induced tube formation. study period, the extent of angiogenesis, apoptosis, and histology were assessed in the excess fat grafts. The results were compared to vascular endothelial growth factor (VEGF)-treated and phosphate-buffered saline (PBS)-treated excess fat grafts. The excess weight and volume of the EPO-treated grafts were higher than those of the PBS-treated grafts, whose weights and volumes were not different from those of the VEGF-treated grafts. EPO treatment also increased the expression of angiogenic factors and microvascular density, and reduced inflammation and apoptosis in a dose-dependent manner in the excess fat grafts. == Conclusions/Significance == Our data suggest that activation of angiogenesis by a cluster of angiogenic factors and decreased excess fat cell apoptosis account for potential mechanisms that underlie the improved long-term survival of excess fat transplants following EPO treatment. == Introduction == During angiogenesis, endothelial cells can produce proteases such as matrix metalloproteinases (MMPs), and can increase their ability to migrate and proliferate[1]. This process depends on the activity of several growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF)-BB[2],[3],[4]. Erythropoietin (EPO), a glycoprotein hormone that stimulates erythropoiesis, also instigates the secretion of angiogenic factors[5],[6]. Ribatti and colleagues exhibited that EPO induced a pro-angiogenic phenotype in cultured endothelial cells, and stimulated angiogenesis in vivo[7],[8]. It also stimulated angiogenesis indirectly in ischemic tissue by increasing the expression of VEGF and by recruiting endothelial progenitor cells[9],[10]. In rats, EPO administration mobilized bone marrow-derived progenitor cells[11]and increased the myocardial expression of VEGF[12]. Wanget al.exhibited that EPO can promote angiogenesis by stimulating VEGF secretion from neural progenitor cells and VEGF-receptor expression in cerebral endothelial cells[13]. Other non-hematopoietic effects of EPO include cytoprotection of vascular endothelial cells[14],[15]and anti-apoptotic actions in vascular easy muscle mass cells and endothelial cells[16]such as prevention of mitochondrial release of cytochrome c, suppression of Rabbit Polyclonal to MZF-1 caspase activity, and upregulation of the activity of the protein kinase B (PKB) signaling pathway and the expression of the antiapoptotic protein Bcl-xl[17],[18]. Autologous excess fat transplantation is usually a common and ideal technique for soft tissue augmentation and for filling soft tissue defects due to trauma or aging[19]. Emerging evidence suggests that early and adequate vascularization of the excess fat graft is essential for its take and viability[20],[21]. However, the relatively high resorption rate of the excess fat graft reduces the efficacy of this technique because the volume of vascularized grafts continues to decline as a result of increased excess fat cell death after its transplantation[22]. Although angiogenic factors[23],[24], and VEGF gene therapy, have been individually used to stimulate angiogenesis in excess fat grafts Anidulafungin in order to enhance excess fat cell survival and viability[21],[25],[26], the clinical outcome has been disappointing, because a single angiogenic factor to stimulate angiogenesis may be inadequate[27]. Therefore, reducing the resorption rate of transplanted excess fat is a clinical challenge. In light of all these findings, we hypothesized that treatment of excess fat grafts with EPO would (a) stimulate the release of several angiogenic factors and promote angiogenesis, and (b) prevent apoptosis in excess fat grafts. By Anidulafungin using this working hypothesis, we initiated a study whose aims were (a) to evaluate and compare the effects of VEGF and EPO on excess fat cell survival and angiogenesis in human transplanted excess fat tissue, and (b) to investigate the long-term survival of grafted excess fat cells after EPO treatment in immunologically-compromised nude mice. == Materials and Methods == == Isolation and preparation of human excess fat tissue == Excess fat was harvested from your thigh of a 40-year-old woman undergoing suction-assisted lipectomy under general anesthesia. In order to decrease bleeding during Anidulafungin excess fat aspiration, and to relieve pain after the process, the areas for aspiration were injected with a local anesthesia solution made up of lidocaine (0.5%) and adrenaline (11,000,000) before the beginning of the process. The excess fat was aspirated using a 14-gauge three-hole blunt cannula, and then processed under sterile conditions for subsequent grafting into nude mice within two hours of its collection according to previously published protocols[28],[29]. The participant gave her written informed consent, and the study was examined and approved by the institutional review table of the Rambam Health Care Campus. == Study design == Two different animal studies Anidulafungin were conducted,.